Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
GAITHERSBURG, Md., Feb. 09, 2017 -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, February 23, 2017 at 5:00 pm (Eastern Time) to discuss the financial results for the fourth quarter and full twelve months of 2016, recent business developments, financial outlook for full year 2017, and revenue guidance for the first quarter of 2017.
This conference call can be accessed live by telephone or via webcast:
| Live Teleconference Information: |
| Dial in number: (855) 766-6521 |
| International dial in: (262) 912-6157 |
| Conference ID: 29688886 |
| Live Webcast Information: |
| Visit edge.media-server.com/m/p/qbs3g23i for the live webcast feed. |
A replay of the call can be accessed on Emergent’s website emergentbiosolutions.com under “Investors.”
About Emergent BioSolutions
Emergent BioSolutions Inc. is a global life sciences company seeking to protect and enhance life by focusing on providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at emergentbiosolutions.com. Follow us @emergentbiosolu.
Investor Contact: Robert G. Burrows Vice President, Investor Relations 240-631-3280 [email protected] Media Contact: Tracey Schmitt Lintott Senior Vice President, Global Public Affairs 240-631-3281 [email protected]
